The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Liprimar     (3R,5R)-7-[2-(4- fluorophenyl)-3-phenyl-4...

Synonyms: Atorlip, Atorpic, Faboxim, Lipitor, Torvacard, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cardyl


Psychiatry related information on Cardyl


High impact information on Cardyl


Chemical compound and disease context of Cardyl


Biological context of Cardyl


Anatomical context of Cardyl


Associations of Cardyl with other chemical compounds


Gene context of Cardyl

  • The activity of PLTP in type 2 diabetes is decreased by atorvastatin [27].
  • Atorvastatin also increased ABCA1 and ABCG1 mRNA abundance (30 and 35%, p < 0.05) [28].
  • Cis-inhibition studies indicate that both OATP2 and roatp1 also transport other statins including lovastatin, simvastatin, and atorvastatin [29].
  • SUBJECTS, MATERIALS AND METHODS: Plasma APOA5 concentration was measured by ELISA in 215 subjects with type 2 diabetes, who were taken from the Diabetes Atorvastatin Lipid-lowering Intervention (DALI) study, a 30-week randomised, double-blind, placebo-controlled study, and given atorvastatin 10 mg or 80 mg daily [30].
  • The effect of atorvastatin on adiponectin and resistin levels was investigated in a 12-week-long randomized, double-blind, placebo-controlled study [31].

Analytical, diagnostic and therapeutic context of Cardyl


  1. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Youssef, S., Stüve, O., Patarroyo, J.C., Ruiz, P.J., Radosevich, J.L., Hur, E.M., Bravo, M., Mitchell, D.J., Sobel, R.A., Steinman, L., Zamvil, S.S. Nature (2002) [Pubmed]
  2. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Bakker-Arkema, R.G., Davidson, M.H., Goldstein, R.J., Davignon, J., Isaacsohn, J.L., Weiss, S.R., Keilson, L.M., Brown, W.V., Miller, V.T., Shurzinske, L.J., Black, D.M. JAMA (1996) [Pubmed]
  3. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D., Ganz, P., Oliver, M.F., Waters, D., Zeiher, A., Chaitman, B.R., Leslie, S., Stern, T. JAMA (2001) [Pubmed]
  4. Toxic epidermal necrolysis from atorvastatin. Pfeiffer, C.M., Kazenoff, S., Rothberg, H.D. JAMA (1998) [Pubmed]
  5. The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. Stein, E. Atherosclerosis. Supplements. (2002) [Pubmed]
  6. Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression? Miida, T., Takahashi, A., Tanabe, N., Ikeuchi, T. Curr. Opin. Lipidol. (2005) [Pubmed]
  7. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Olsson, A.G., Schwartz, G.G., Szarek, M., Sasiela, W.J., Ezekowitz, M.D., Ganz, P., Oliver, M.F., Waters, D., Zeiher, A. Eur. Heart J. (2005) [Pubmed]
  8. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Yee, H.S., Fong, N.T. The Annals of pharmacotherapy. (1998) [Pubmed]
  9. Effect of Atorvastatin on Cognitive Function in Patients from the Lipid Lowering and Onset of Renal Disease (LORD) Trial. Summers, M.J., Oliver, K.R., Coombes, J.S., Fassett, R.G. Pharmacotherapy (2007) [Pubmed]
  10. Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Sparks, D.L., Petanceska, S., Sabbagh, M., Connor, D., Soares, H., Adler, C., Lopez, J., Ziolkowski, C., Lochhead, J., Browne, P. Current Alzheimer research. (2005) [Pubmed]
  11. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. Pitt, B., Waters, D., Brown, W.V., van Boven, A.J., Schwartz, L., Title, L.M., Eisenberg, D., Shurzinske, L., McCormick, L.S. N. Engl. J. Med. (1999) [Pubmed]
  12. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Swamy, M.V., Patlolla, J.M., Steele, V.E., Kopelovich, L., Reddy, B.S., Rao, C.V. Cancer Res. (2006) [Pubmed]
  13. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Reddy, B.S., Wang, C.X., Kong, A.N., Khor, T.O., Zheng, X., Steele, V.E., Kopelovich, L., Rao, C.V. Cancer Res. (2006) [Pubmed]
  14. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. Lawman, S., Mauri, C., Jury, E.C., Cook, H.T., Ehrenstein, M.R. J. Immunol. (2004) [Pubmed]
  15. Assessment of the efficacy of different statins in murine collagen-induced arthritis. Palmer, G., Chobaz, V., Talabot-Ayer, D., Taylor, S., So, A., Gabay, C., Busso, N. Arthritis Rheum. (2004) [Pubmed]
  16. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. Gegg, M.E., Harry, R., Hankey, D., Zambarakji, H., Pryce, G., Baker, D., Adamson, P., Calder, V., Greenwood, J. J. Immunol. (2005) [Pubmed]
  17. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. Dunn, S.E., Youssef, S., Goldstein, M.J., Prod'homme, T., Weber, M.S., Zamvil, S.S., Steinman, L. J. Exp. Med. (2006) [Pubmed]
  18. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Guijarro, C., Blanco-Colio, L.M., Ortego, M., Alonso, C., Ortiz, A., Plaza, J.J., Díaz, C., Hernández, G., Egido, J. Circ. Res. (1998) [Pubmed]
  19. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Ikeda, M., Abe, K., Yamada, M., Dansako, H., Naka, K., Kato, N. Hepatology (2006) [Pubmed]
  20. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Fromigu??, O., Ha??, E., Modrowski, D., Bouvet, S., Jacquel, A., Auberger, P., Marie, P.J. Cell Death Differ. (2006) [Pubmed]
  21. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Chan, D.C., Watts, G.F., Barrett, P.H., Beilin, L.J., Redgrave, T.G., Mori, T.A. Diabetes (2002) [Pubmed]
  22. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. Aktas, O., Waiczies, S., Smorodchenko, A., Dorr, J., Seeger, B., Prozorovski, T., Sallach, S., Endres, M., Brocke, S., Nitsch, R., Zipp, F. J. Exp. Med. (2003) [Pubmed]
  23. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Hernández-Perera, O., Pérez-Sala, D., Navarro-Antolín, J., Sánchez-Pascuala, R., Hernández, G., Díaz, C., Lamas, S. J. Clin. Invest. (1998) [Pubmed]
  24. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Smilde, T.J., van Wissen, S., Wollersheim, H., Trip, M.D., Kastelein, J.J., Stalenhoef, A.F. Lancet (2001) [Pubmed]
  25. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003. Shepherd, J., Hunninghake, D.B., Barter, P., McKenney, J.M., Hutchinson, H.G. Atherosclerosis. Supplements. (2004) [Pubmed]
  26. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. Stüve, O., Youssef, S., Weber, M.S., Nessler, S., von Büdingen, H.C., Hemmer, B., Prod'homme, T., Sobel, R.A., Steinman, L., Zamvil, S.S. J. Clin. Invest. (2006) [Pubmed]
  27. Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein e? Dallinga-Thie, G.M., van Tol, A., Hattori, H., Rensen, P.C., Sijbrands, E.J. Diabetes (2006) [Pubmed]
  28. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. Argmann, C.A., Edwards, J.Y., Sawyez, C.G., O'Neil, C.H., Hegele, R.A., Pickering, J.G., Huff, M.W. J. Biol. Chem. (2005) [Pubmed]
  29. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.P., Kirchgessner, T.G. J. Biol. Chem. (1999) [Pubmed]
  30. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Dallinga-Thie, G.M., van Tol, A., Hattori, H., van Vark-van der Zee, L.C., Jansen, H., Sijbrands, E.J. Diabetologia (2006) [Pubmed]
  31. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Shetty, G.K., Economides, P.A., Horton, E.S., Mantzoros, C.S., Veves, A. Diabetes Care (2004) [Pubmed]
WikiGenes - Universities